Alloy Therapeutics and Echo Investment Capital have formed Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact. Wheeler’s discovery-to-IND programs are designed to provide emerging biopharma companies a faster and more predictable path to the clinic.
 
With an initial focus on antibody therapeutics, Wheeler’s biomanufacturing programs will integrate with Alloy Therapeutic’s preclinical antibody platforms and discovery capabilities. Wheeler’s state-of-the-art development and cGMP operations and business headquarters are located in Oklahoma City, OK and are supported by a pilot lab inside Alloy’s Boston, MA facility.
 
“Accelerating the translation of therapeutic innovation into clinical impact in the biopharma industry requires new kinds of biomanufacturing businesses. We created Wheeler Bio to provide best-in-class biomanufacturing speed, capabilities, and service to the next generation of drug developers,” said Jesse McCool, co-founder and CEO, Wheeler. “Through our parallel integration with discovery and unique partnering model, we will be able to offer customers groundbreaking turnaround times at fair prices.”
 
Errik Anderson, founder and CEO, Alloy Therapeutics, said, “Finding a CDMO that cares as much about your preclinical batches as your commercial batches is a challenge we regularly face in drug development. Alloy is excited to partner with Wheeler and is confident that Jesse and his team will deliver the turnkey and high-quality CMC services that Alloy’s ecosystem of partners require to achieve their clinical goals. What Wheeler is building aligns completely with Alloy’s mission to democratize access to foundational drug development technologies and capabilities.”
 
Wheeler launched its Boston-based operations in the first quarter of 2021 and will open its 35,000 square foot cGMP Oklahoma City facility in the fourth quarter of 2022. Through its partnership with Echo Investment Capital, Wheeler will have preferred access to expand its biomanufacturing offering to commercial scale production in the recently announced 400,000 square foot manufacturing complex in the Oklahoma City Innovation District.